Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-09-21 DOI:10.1080/14737140.2025.2560941

Abdel-Hameed Ibrahim Mohamed Ebid, Yasmine Magdy Fahim Genina, Hesham Raafat Shawky Haffez, Sherif Hassanien Ahmed Hakam, Loay Mohamed Hassan Kassem, Sara Mohamed Mohamed AbdelMotaleb

{"title":"Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.","authors":"Abdel-Hameed Ibrahim Mohamed Ebid, Yasmine Magdy Fahim Genina, Hesham Raafat Shawky Haffez, Sherif Hassanien Ahmed Hakam, Loay Mohamed Hassan Kassem, Sara Mohamed Mohamed AbdelMotaleb","doi":"10.1080/14737140.2025.2560941","DOIUrl":null,"url":null,"abstract":"Background: Palbociclib is a cornerstone treatment for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer.Research design and methods: This retrospective cohort study included 140 patients who were resistant to endocrine therapy and received palbociclib in combination with endocrine therapy. It is aimed to evaluate the efficacy and tolerability of palbociclib and to identify factors influencing progression-free survival and overall survival.Results: A total of 140 were enrolled in the study; 57 and 83 patients were primary and secondary resistance to endocrine therapy, respectively. In the whole cohort, regarding progression-free survival; low Ki-67 and incidence of moderate-to-severe (grade 3/4) neutropenia were associated with longer median progression-free survival with p-values of 0.004 (3.7 vs. 8.4 months) and 0.026 (4.7 vs. 6.5 months), respectively. Regarding overall survival, duration on palbociclib (≥12 months) had longer overall survival compared with patients who received palbociclib <12 months (p = 0.0012). The overall survival was longer in the secondary-resistant group than in the primary-resistant group (log-rank test p = 0.0003).Conclusion: In a metastatic setting, low Ki-67 and moderate-to-severe neutropenia are associated with better survival outcomes in endocrine resistant patients treated with palbociclib (Clinical trial registration: www.clinicaltrials.gov identifier is NCT06338644).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2560941","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Palbociclib is a cornerstone treatment for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer.

Research design and methods: This retrospective cohort study included 140 patients who were resistant to endocrine therapy and received palbociclib in combination with endocrine therapy. It is aimed to evaluate the efficacy and tolerability of palbociclib and to identify factors influencing progression-free survival and overall survival.

Results: A total of 140 were enrolled in the study; 57 and 83 patients were primary and secondary resistance to endocrine therapy, respectively. In the whole cohort, regarding progression-free survival; low Ki-67 and incidence of moderate-to-severe (grade 3/4) neutropenia were associated with longer median progression-free survival with p-values of 0.004 (3.7 vs. 8.4 months) and 0.026 (4.7 vs. 6.5 months), respectively. Regarding overall survival, duration on palbociclib (≥12 months) had longer overall survival compared with patients who received palbociclib <12 months (p = 0.0012). The overall survival was longer in the secondary-resistant group than in the primary-resistant group (log-rank test p = 0.0003).

Conclusion: In a metastatic setting, low Ki-67 and moderate-to-severe neutropenia are associated with better survival outcomes in endocrine resistant patients treated with palbociclib (Clinical trial registration: www.clinicaltrials.gov identifier is NCT06338644).

查看原文本刊更多论文

帕博西尼治疗内分泌耐药转移性乳腺癌：现实世界的结果。

背景：帕博西尼是激素受体阳性和人表皮生长因子受体2阴性转移性乳腺癌患者的基础治疗。研究设计与方法：本回顾性队列研究纳入140例内分泌治疗耐药患者，接受帕博西尼联合内分泌治疗。目的是评估帕博西尼的疗效和耐受性，并确定影响无进展生存期和总生存期的因素。结果：共有140人入组；原发性耐药57例，继发性耐药83例。在整个队列中，关于无进展生存期；低Ki-67和中重度（3/4级）中性粒细胞减少的发生率与较长的中位无进展生存期相关，p值分别为0.004 （3.7 vs 8.4个月）和0.026 （4.7 vs 6.5个月）。关于总生存期，帕博西尼的持续时间（≥12个月）比接受帕博西尼的患者的总生存期更长。结论：在转移性环境中，低Ki-67和中重度中性粒细胞减少与接受帕博西尼治疗的内分泌抵抗患者的生存结局相关。（临床试验注册：www.clinicaltrials.gov标识符：NCT06338644）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.